share_log

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $14

Chardan Capital Maintains Buy on Better Therapeutics, Lowers Price Target to $14

Chardan Capital維持買入Better Treatetics,將目標價下調至14美元
Benzinga Real-time News ·  2022/11/15 07:06

Chardan Capital analyst Keay Nakae maintains Better Therapeutics (NASDAQ:BTTX) with a Buy and lowers the price target from $17 to $14.

Chardan Capital分析師Keay Nakae維持了Better Treateutics(納斯達克:BTTX)的買入,並將目標價從17美元下調至14美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論